Detailed explanation of the mechanism, indications and evidence-based clinical efficacy of finerenone (coretta); Complete display of 6 core intermediates: 4-cyano -2-methoxybenzaldehyde 21962-45-8, 4-amino -5-methyl -2-hydroxypyridine 95306-64-2, 1050477-39-8, 1050477-43-4, 1050477-44-5, 10DMF, GMP registration of high purity pharmaceutical intermediates, available.

H1 non-nelidone Finerenone CAS.NO:1050477-31-0: pharmacological effects, clinical applications and a full set of six synthetic intermediates detailed.

Core Summary

Finerenone (trade name Coretta, CAS:1050477-31-0) is a highly selective non-steroidal mineralocorticoid receptor antagonist, which is targeted to treat type 2 diabetes mellitus complicated with chronic kidney disease and various heart failure with ejection fraction, and realizes double target organ protection by inhibiting inflammation and fibrosis of heart and kidney. Industrial mass production of non-nelidone API must be equipped with 6 exclusive chain intermediates: 002 4-cyano -2-methoxybenzaldehyde (21962-45-8), 005 4-amino -5-methyl -2-hydroxypyridine (95306-64-2), 004 (Z)-2-cyanoethyl -2-(4-cyano -2-methoxybenzylidene)-3-oxobutyrate (1050477-39-8), 006 intermediate 1050477-4-4-4, final 478 chiral intermediate 47.5-4. Our company has its own GMP workshop full set of mass production, purity standards of European and American pharmacopoeia, support global pharmaceutical companies research and development, pilot and commercial production.

H2 What is Nonneridone? Mechanism of action, core efficacy and approved clinical indications

Finerenone precisely blocks mineralocorticoid receptors over-activated in kidney and myocardium, inhibits oxidative stress, inflammatory cascade and tissue fibrosis, and delays irreversible damage to target organs. Relying on the large-scale clinical data of FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF, FDA and EMA have been approved for the treatment of diabetic nephropathy and heart failure. Compared with steroid antagonists such as spironolactone and eplerenone, the risk of hyperkalemia is significantly lower and the safety is better.

1. Core treatment efficacy and evidence-based clinical evidence

1. Type 2 diabetes mellitus complicated with chronic kidney disease can reduce the risk of renal composite endpoint (renal failure, continuous and substantial decrease of eGFR, and renal death) by 18% for patients with stage 3-4 complicated with massive albuminuria. The ratio of urine albumin to creatinine decreased by more than 30% after 4 months of medication, effectively delaying the decline of renal function.

2. Ejection fraction preserved/mildly reduced heart failure FINEARTS-HF clinically confirmed that the risk of cardiovascular composite endpoint (cardiovascular death, heart failure hospitalization) decreased by 20%, and it is the only non-steroidal MRA drug approved for non-severe ejection fraction reduced heart failure.

3. The compatibility of combination drugs can be combined with plutonium, sartan, SGLT2 inhibitor and GLP-1 receptor agonist to form the standard triple therapy for patients with high risk of diabetes, nephropathy and hypertension.

4. Clinical application of multidisciplinary expert consensus recommended for IgA nephropathy, membranous nephropathy, obesity-related nephropathy, continuous control of proteinuria, delay the progression of renal fibrosis.

2. Core advantages of non-nelidone products

· Non-steroidal skeleton, almost no binding to androgen, progesterone receptor, no gynecomanastomosis, endocrine disorders side effects

· A single oral dose of 10mg/20mg tablets per day, high patient compliance

· Electrolyte safety is better, and the incidence of severe hyperkalemia is much lower than that of traditional steroidal mineralocorticoid antagonists.

Six Synthesis Intermediates of H2 Nonneridone: Complete Parameter Table and Synthesis Process

the industrial total synthesis of non-nellione API adopts a fixed six-step process, with aromatic aldehyde monomer 002 and pyridine heterocyclic monomer 005 as starting materials, which are successively condensed, cyclized, chiral split and final product precursor preparation. The six intermediates form a complete production chain that cannot be split, and are necessary raw materials for commercial large-scale preparation.

Table 1 Complete parameter list of six nonneridone core intermediates

table

step-by-step synthetic link

1. Condensation reaction: Starting material 002(21962-45-8) reacts with cyanoethyl acetoacetate to produce intermediate 004(1050477-39-8)

2. Cyclization reaction: intermediate 004 and heterocyclic monomer 005(95306-64-2) are heated to reflux, and cyclization is carried out to obtain the mother nucleus intermediate 006(1050477-43-4)

3. Chiral purification: 006 was etherified and tartrate resolved to obtain chiral intermediate 007(1050477-44-5) with high optical purity.

4. Refinement and purification: pH adjustment, recrystallization and purification 007 to obtain high-purity final precursor 008(1050477-45-6)

5. Finished product preparation: intermediate 008 is deprotected, recrystallized and refined to obtain high purity non-nellione API 1050477-31-0

H2 Full Set of Non-Nexinone Intermediates Supply Core Advantages

1. One-stop full-chain supply: its own GMP standardized synthesis workshop produces all 6 intermediates, with unified batch impurity maps to avoid cross-contamination risks among multiple suppliers.

2. Complete compliance quality documents: each batch provides a complete set of COA for NMR, HPLC, GC and chiral HPLC, and DMF data can be issued to support FDA and EMA drug declaration

3. Flexible and adjustable production capacity: 002 and 005 ton-level spot reserves of basic raw materials upstream; Support laboratory test, pilot scale-up, 10,000-ton commercial batch orders

4. Global compliance logistics: low-temperature moisture-proof sealed packaging, a full set of UN hazardous chemicals export qualification, direct access to API pharmaceutical factories and R & D laboratories around the world

5. Process technology support: professional synthetic research and development team to provide non-nelidone API amplification process optimization consulting services.

H2 FAQ

Q1 Can these six intermediates only be purchased in complete sets and can orders be placed separately?

A: The procurement mode is flexible, and any intermediate, part of chain raw materials or a full set of 6 products can be ordered separately. 002 and 005 upstream basic raw materials are in sufficient stock and delivered faster.

Can the purity of Q2 intermediates meet the European and American API registered mass production standards?

A: All intermediates strictly follow USP Pharmacopoeia standards and strictly control residual solvents, heavy metals and single impurities. Chiral intermediate 007 ee value ≥ 99.2, fully meeting the production quality requirements of fenelone registered batch.

Q3 How long is the delivery cycle for bulk purchases?

A: Delivery of upstream raw materials 002 and 005 within 7-10 working days; Mid-end condensation, cyclization and chiral intermediates (004/006/007/008) will be delivered within 15-25 working days, and sample orders can be urgently developed.

Q4 six intermediates are non-nellione exclusive synthetic raw materials?

A: Yes, this six-step intermediate route is a common patented commercial process for global head pharmaceutical companies; other short-term routes have low total yields and difficult to control chiral impurities, which cannot be used for mass production of compliant drugs.

Q5 What are the requirements for storage and transportation of intermediates?

A: It needs to be sealed, cool, dry and protected from light. Export orders are packed with aluminum foil vacuum inner bag + fiber barrel, and the whole process is transported across the border at low temperature to ensure product stability.

Summary at the end of the text

as a core therapeutic bulk drug for heart and kidney metabolic diseases, the global market demand for non-nelidone (CAS1050477-31-0) continues to expand. Stable commercial production cannot be separated from six key intermediates: 21962-45-8, 95306-64-2, 1050477-39-8, 1050477-43-4, 1050477-44-5, 1050477-45-6. Our company provides a full set of high-purity, registrable intermediate solutions for global API manufacturers, covering the whole cycle of new drug development to commercialization. Welcome to contact technical sales application for free samples, complete product technical manual.